| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/SLA.0B013E318263DA2F |
| P698 | PubMed publication ID | 22968073 |
| P50 | author | Jennifer Wargo | Q32650026 |
| Keith D Lillemoe | Q103302432 | ||
| P2093 | author name string | David P Ryan | |
| Andrew L Warshaw | |||
| Theodore S Hong | |||
| Eunice L Kwak | |||
| Vikram Deshpande | |||
| Lawrence S Blaszkowsky | |||
| Gregory Y Lauwers | |||
| Cristina R Ferrone | |||
| Jill N Allen | |||
| Ioannis T Konstantinidis | |||
| Carlos Fernandez-Del Castillo | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | invasive ductal carcinoma | Q1671685 |
| pancreatic ductal carcinoma | Q8263002 | ||
| pancreatic ductal adenocarcinoma | Q18555956 | ||
| P304 | page(s) | 731-736 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Annals of Surgery | Q4767866 |
| P1476 | title | Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? | |
| P478 | volume | 257 |
| Q52603515 | A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. |
| Q41598569 | A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma |
| Q47322884 | A portable high-intensity focused ultrasound system for the pancreas with 3D electronic steering: a preclinical study in a swine model. |
| Q51038646 | A replaced right hepatic artery adjacent to pancreatic carcinoma should be divided to obtain R0 resection in pancreaticoduodenectomy. |
| Q38102914 | Advanced-stage pancreatic cancer: therapy options |
| Q91622958 | Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma |
| Q38290146 | Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration |
| Q38908575 | Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. |
| Q38726457 | Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer |
| Q48772394 | Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer |
| Q55022845 | Clinical implication of surgical resection for recurrent biliary tract cancer: Does it work or not? |
| Q60932899 | Clinical significance of revised microscopic positive resection margin status in ductal adenocarcinoma of pancreatic head |
| Q33891283 | Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. |
| Q37376094 | Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic |
| Q42041224 | Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy |
| Q53098497 | Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study. |
| Q64054091 | Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study |
| Q47341561 | Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. |
| Q64099914 | Differentiation between non-hypervascular pancreatic neuroendocrine tumour and pancreatic ductal adenocarcinoma on dynamic computed tomography and non-enhanced magnetic resonance imaging |
| Q52339747 | Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectom |
| Q37722157 | En bloc vascular resection for the treatment of borderline resectable pancreatic head carcinoma |
| Q52560203 | Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. |
| Q33914066 | Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma |
| Q90385406 | Extended distal pancreatectomy with thoracic wall resection after neoadjuvant FOLFIRINOX: Is there a limit of resection for pancreatic cancer after downstaging? |
| Q48513073 | Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors |
| Q46277412 | FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis |
| Q37480826 | Friday, February 21, 2014, 5:00pm–6:30pm Oral Poster I (Liver I, II; Pancreas I, II; Biliary I; Transplant I; Other) |
| Q33870913 | Identifying the neck margin status of ductal adenocarcinoma in the pancreatic head by multiphoton microscopy |
| Q36113317 | Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis |
| Q35925005 | Impact of centralization of pancreatoduodenectomy on reported radical resections rates in a nationwide pathology database |
| Q38147548 | Improvement of surgical results for pancreatic cancer |
| Q64974733 | Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins. |
| Q93136804 | International consensus statement on robotic pancreatic surgery |
| Q90214713 | Intra-Operative Frozen Section Histology of the Pancreatic Resection Margins and Clinical Outcome of Patients with Adenocarcinoma of the Head of the Pancreas Undergoing Pancreaticoduodenectomy |
| Q55371506 | Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation. |
| Q35875903 | LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution |
| Q90643901 | Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma |
| Q37204959 | Mesopancreatic Stromal Clearance Defines Curative Resection of Pancreatic Head Cancer and Can Be Predicted Preoperatively by Radiologic Parameters: A Retrospective Study |
| Q38689857 | Metabolomics applications in precision medicine: An oncological perspective |
| Q38196402 | Minireview on laparoscopic hepatobiliary and pancreatic surgery |
| Q90038743 | Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe |
| Q36152545 | Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study |
| Q33418472 | Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas |
| Q92486874 | Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis |
| Q33809495 | Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival |
| Q42374126 | Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. |
| Q49966077 | Obesity and Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by Weight Loss |
| Q36879789 | Opportunities of improvement in the management of pancreatic and periampullary tumors. |
| Q36076312 | PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma |
| Q39014043 | Palliative Care for Pancreatic and Periampullary Cancer |
| Q92972872 | Palliative therapy in pancreatic cancer-palliative surgery |
| Q34778217 | Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis |
| Q28072182 | Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions |
| Q36281575 | Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management |
| Q30241486 | Pancreatic cancer and liver metastases: state of the art. |
| Q38288556 | Pancreatic cancer metastasis: are we being pre-EMTed? |
| Q34036659 | Pancreatic cancer-improved care achievable |
| Q28076803 | Pancreatic cancer: Open or minimally invasive surgery? |
| Q55326300 | Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center. |
| Q90321535 | Portal-Mesenteric Vein Resection in Borderline Pancreatic Cancer; 33 Month-Survival in Patients with Good Performance Status |
| Q85848497 | Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients |
| Q51751748 | Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. |
| Q92331001 | Proposal for a definition of "Oligometastatic disease in pancreatic cancer" |
| Q50185212 | Quality of life and visceral surgery |
| Q35147520 | Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer |
| Q28075892 | Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas |
| Q53519369 | Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion. |
| Q47998977 | Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. |
| Q91804370 | Retrospective analysis of seven cases of pancreatic mixed adenoneuroendocrine carcinoma from a high-volume center and review of the literature |
| Q98465820 | Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer |
| Q57164749 | Revision of Surgical Margin under Frozen Section to Achieve R0 Status on Survival in Patients with Pancreatic Cancer |
| Q87526045 | S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas |
| Q92055156 | Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma |
| Q34513935 | Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer |
| Q88427558 | Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection |
| Q38234195 | Surgical management of pancreatic neoplasms: what's new? |
| Q38538721 | Surgical resection strategies for locally advanced pancreatic cancer |
| Q88213642 | Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection |
| Q26747291 | Targeting mTOR in Pancreatic Ductal Adenocarcinoma |
| Q90420014 | The YAP1-NMU Axis Is Associated with Pancreatic Cancer Progression and Poor Outcome: Identification of a Novel Diagnostic Biomarker and Therapeutic Target |
| Q36747432 | The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection |
| Q96955060 | The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor |
| Q40563842 | The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. |
| Q38689578 | The lymphatic system and pancreatic cancer |
| Q90398573 | The relationship between pancreatic cancer and type 2 diabetes: cause and consequence |
| Q38926612 | Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma |
| Q55069065 | Tumor heterogeneity of pancreas head cancer assessed by CT texture analysis: association with survival outcomes after curative resection. |
| Q52673026 | Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. |
| Q57110361 | Tumour origin and R1 rates in pancreatic resections: towards consilience in pathology reporting |
| Q43199953 | Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology? |
| Q52609132 | ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. |
| Q53194479 | [R1 resection for pancreatic carcinoma]. |
| Q53143330 | [Resectability of pancreatic cancer: New criteria]. |
| Q89737178 | miR-193a-5p promotes pancreatic cancer cell metastasis through SRSF6-mediated alternative splicing of OGDHL and ECM1 |
| Q58760423 | p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation |
| Q37435242 | uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection |
Search more.